Article Text

Download PDFPDF
Gestational trophoblastic tumors: cytostatic treatment response evaluated from hCG modelling
  1. C. TropÉ and
  2. J. Carl*,
  1. * Department of Oncology, Aalborg Hospital, and
  2. Department of Gynaecologic Oncology, The Norwegian Radium Hospital, Oslo Norway;
  3. Department of Experimental Clinical Oncology, Danish Cancer Society, Denmark
  1. Address for correspondence: Jesper Carl, Department of Oncology, Aalborg City Hospital, section South, 18-22 Hobrovej, DK-9100 Aalborg, Denmark.


Five patients, three high risk and two medium risk, were allocated to a high dose methotrexate regimen. Surviving fractions of hCG-producing cells in high dose methotrexate were a factor of 3–10 times lower than the surviving cell fractions in the low dose regimen, indicating a biphasic dose-response relation for methotrexate. Medium risk patients were found to have an unacceptably high recurrence rate after methotrexate actinomycin-D therapy and should be treated with more intensive chemotherapy. It is recommended that drug dose should be corrected for body-volume in low risk regimes, to avoid drug resistance developing because of increased treatment time.

  • actinomycin
  • gestational trophoblastic tumors
  • human chorionic gonadotrophin
  • mathematical model
  • methotrexate
  • prognostic fctors
  • treatment response.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.